Suven Life Sciences - Patent Granted

Suven Life Sciences Ltd on December 27, 2007 has announced that the US Patent office has granted Product Patent # US 7,297,711 to Suven. This is Suven's first product patent granted in USA. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents. According to the invention '711 patent disclosure, the compounds are useful in the treatment of neuro-degenarative disorders like Alzheimer's Parkinson, Schizophrenia and Huntington's.

Suven has so far filed 29 product patent applications through PCT covering more than 145 countries, out of which 5 patents are granted in various countries. There are several other patent applications from Suven Discovery Research are in the pipeline that have completed the administrative and technical diligence from the patent offices from major countries and would be granted shortly.

Suven has filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.

"We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS disorders which targets a $18 billion potential market opportunity" says Venkat Jasti, CEO of Suven.

Suven Life Sciences - Keep Heart

Suven, US Firm To Develop Cardiovascular Drugs

Hyderabad-based drug developer Suven Life Sciences will soon sign a formal agreement with a top US-based pharma company to jointly develop new drugs for cardiovascular diseases. As part of this, Suven will soon expand its drug development centre to accommodate about 500 scientists.

The company already has a drug discovery alliance with another US-based drug company, Eli Lilly.

“We are in talks with an MNC for drug development in the area of cardiovascular diseases and hope to sign the memorandum of understanding (MoU) within a few months. We are, now, not in a position to disclose the identity of the partner,” said Venkat Jasti, chairman and managing director.

The two firms would develop drugs from the pre-clinical stage, including drug discovery, screening, identification and optimisation of potential clinical candidates.

Suven will expand its drugs discovery centre in Hyderabad with an investment of $25 million. Currently, the centre employs about 150 scientists. With the new drug discovery deal in place, the total strength will be increased to 500. The infrastructure would be in place within two years, he said.

Apart from this, Suven is likely to expand its drug discovery alliance with Ei Lilly for target discovery of more molecules in various therapeutic areas. Currently, Suven and Eli Lilly are working to develop drugs targeted for central nervous disorder (CNS) drugs.

Suven is one among the few drug discovery companies in India to rope in alliances with big pharma companies for joint drug research.

Suven has a rich pipeline of drugs under development for CNS disorders like Alzheimer’s disease, schizophrenia and depression and other neourological disorders.

The other major deals in this space include Ranabaxy-GSK alliance to develop drugs for infections, metabolic and respiratory diseases and cancer, Biocon’s tie up with Bristol-Myers Squibb for various disease areas, Advinus and Merck’s collaboration to develop drugs for metabolic disorders, Nicholas Piramal-Eli Lilly programme to develop drugs for metabolic disorders and GVK Biosciences alliance with Eli Lilly to provide basic drug research services.

Its first Investigational New Drug (IND), SUVN-502 for Alzheimer’s disease and schizophrenia, is currently undergoing the first phase of clinical trials in India.

Source : Business Standard

Suven Lifescience - Rewards Investors

Suven Life To Split Stock, Issue 1:1 Bonus

The board of directors of Suven Life Sciences, approved issue of bonus shares in the ratio of 1:1 i.e one bonus share for every share held.

According to a release issued to the BSE, the board meeting also approved a proposal for sub-division of equity shares with a face value of Rs 2 each to Re 1 each.

An EGM will be held on March 10, 2007 for approval of the sub-division of equity shares and issue of bonus shares, the release added.

Suven Life - Secures Patent

Suven Life Sciences Secures Patent From European Patent Office (EPO)

Suven Life Sciences Ltd on January 09, 2007 has announced that the European Patent Office (EPO) issued the Patent 1517909 titled "Novel Tetracyclic Arylcarbonylindoles having Serotonin Receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them" to the Company and is valid until June 2023. The granted claims of the patent include the class of selective 5-HT compounds discovered by the Company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like Attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of the Company.

The Company is a major service provider of Drug Discovery and Development support Services (DDDSS) to global Pharmaceutical, Life Sciences and Biotech Companies in addition to their continued business interest and growth in Contract Research and Manufacturing Services (CRAMS). The Company is a Collaborative Research Partner (CRP) with a Global pharma major since Sept 2006 to Discover NCE's for unmet medical need in CNS.